Compass Therapeutics, Inc. (NASDAQ:CMPX) announced statistically significant topline data on Tuesday on the primary efficacy endpoint for COMPANION-002, the company’s ongoing Phase 2/3 trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results